Revenue Agenda
  • Investing
  • Latest News
  • Editor’s Pick
  • Economy
  • Investing
  • Latest News
  • Editor’s Pick
  • Economy
No Result
View All Result
Revenue Agenda
No Result
View All Result
Home Investing

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

admin by admin
September 21, 2024
in Investing
0
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.

HIGHLIGHTS

The US FDA has granted Fast Track Designation to Amplia’s lead drug narmafotinib in advanced pancreatic cancerFast Track Designation facilitates the development of investigational drugs and allows for expedited review

Fast Track Designation is available to drugs that may provide an advantage over current therapies in the treatment of serious conditions. It is designed to speed the development of these drugs to enable patients to receive them sooner. This Designation will grant the Company access to more frequent meetings, and written communication, with the FDA. In future, narmafotinib may be eligible for Accelerated Approval and Priority Review. The Company has previously received Orphan Drug Designation from the FDA for narmafotinib in pancreatic cancer.

The Company’s CEO and Managing Director, Dr Chris Burns, commented, “Fast Track Designation for narmafotinib is a significant milestone for the Company. With this designation, we can work more closely with the FDA to accelerate our clinical program and gather the most compelling evidence for regulatory approval in this devastating disease.”

Amplia’s clinical trial in advanced pancreatic cancer, the ACCENT trial, is ongoing in Australia and South Korea. Earlier this year, the Company announced that the US FDA had cleared its IND1 application for a trial of narmafotinib in pancreatic cancer in the US. This trial is in advanced planning stages.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

Previous Post

Saskatchewan Research Council Achieves Commercial Production at Rare Earths Facility

Next Post

​Tech 5: Microsoft Taps Three Mile Island to Power AI, Intel Shares New Strategy

Next Post
​Tech 5: Microsoft Taps Three Mile Island to Power AI, Intel Shares New Strategy

​Tech 5: Microsoft Taps Three Mile Island to Power AI, Intel Shares New Strategy

  • Trending
  • Comments
  • Latest
Top 10 Potash Countries by Production (Updated 2024)

Top 10 Potash Countries by Production (Updated 2024)

August 21, 2024
Top 10 Phosphate Countries by Production (Updated 2024)

Top 10 Phosphate Countries by Production (Updated 2024)

August 1, 2024
Top 10 Uranium-producing Countries (Updated 2024)

Top 10 Uranium-producing Countries (Updated 2024)

November 6, 2024
7 Biggest Lithium-mining Companies in 2024

7 Biggest Lithium-mining Companies in 2024

September 18, 2024
Completion of Entitlement Offer

Completion of Entitlement Offer

0
New Hampshire Gov. Sununu signs $15.2B ‘miracle’ budget into law

New Hampshire Gov. Sununu signs $15.2B ‘miracle’ budget into law

0

Pennsylvania House clears tax credits for new teachers, nurses, police officers

0
Evers signs bipartisan sales tax bill aimed at sparing Milwaukee from bankruptcy

Evers signs bipartisan sales tax bill aimed at sparing Milwaukee from bankruptcy

0
Completion of Entitlement Offer

Completion of Entitlement Offer

August 1, 2025
Stallion Uranium Announces Update to Previously Announced Technology Licensing Agreement

Stallion Uranium Announces Update to Previously Announced Technology Licensing Agreement

August 1, 2025
Silver Crown Announces Amendment

Silver Crown Announces Amendment

August 1, 2025
Harvest Gold Announces Closing of Non-Brokered Private Placement with Crescat Capital as Lead Investor

Harvest Gold Announces Closing of Non-Brokered Private Placement with Crescat Capital as Lead Investor

August 1, 2025
Enter Your Information Below To Receive Trading Ideas and Latest News

Error: Contact form not found.

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent News

Completion of Entitlement Offer

Completion of Entitlement Offer

August 1, 2025
Stallion Uranium Announces Update to Previously Announced Technology Licensing Agreement

Stallion Uranium Announces Update to Previously Announced Technology Licensing Agreement

August 1, 2025
Silver Crown Announces Amendment

Silver Crown Announces Amendment

August 1, 2025
Harvest Gold Announces Closing of Non-Brokered Private Placement with Crescat Capital as Lead Investor

Harvest Gold Announces Closing of Non-Brokered Private Placement with Crescat Capital as Lead Investor

August 1, 2025
  • About us
  • Privacy Policy
  • Terms & Conditions
  • About us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 revenueagenda.com | All Rights Reserved

No Result
View All Result
  • Investing
  • Latest News
  • Editor’s Pick
  • Economy

Copyright © 2025 revenueagenda.com | All Rights Reserved